RT Journal Article
SR Electronic
T1 Disruption of RFX family transcription factors causes autism, attention deficit/hyperactivity disorder, intellectual disability, and dysregulated behavior
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.09.20187104
DO 10.1101/2020.09.09.20187104
A1 Holly K. Harris
A1 Tojo Nakayama
A1 Jenny Lai
A1 Boxun Zhao
A1 Nikoleta Argyrou
A1 Cynthia S. Gubbels
A1 Aubrie Soucy
A1 Casie A. Genetti
A1 Lance H. Rodan
A1 George E. Tiller
A1 Gaetan Lesca
A1 Karen W. Gripp
A1 Reza Asadollahi
A1 Ada Hamosh
A1 Carolyn D. Applegate
A1 Peter D. Turnpenny
A1 Marleen E.H. Simon
A1 Catharina (Nienke) M.L. Volker-Touw
A1 Koen L.I. van Gassen
A1 Ellen van Binsbergen
A1 Rolph Pfundt
A1 Thatjana Gardeitchik
A1 Bert B.A. de Vries
A1 Ladonna L. Imken
A1 Catherine Buchanan
A1 Marcia Willing
A1 Tomi L. Toler
A1 Emily Fassi
A1 Laura Baker
A1 Fleur Vansenne
A1 Xiadong Wang
A1 Julian L. Ambrus, Jr.
A1 Madeleine Fannemel
A1 Jennifer E. Posey
A1 Emanuele Agolini
A1 Antonio Novelli
A1 Anita Rauch
A1 Paranchai Boonsawat
A1 Christina R. Fagerberg
A1 Martin J. Larsen
A1 Maria Kibaek
A1 Audrey Labalme
A1 Alice Poisson
A1 Katelyn K. Payne
A1 Laurence E. Walsh
A1 Kimberly Aldinger
A1 Jorune Balciuniene
A1 Cara Skraban
A1 Christopher Gray
A1 Jill Murrell
A1 Caleb P. Bupp
A1 Giulia Pascolini
A1 Paola Grammatico
A1 Martin Broly
A1 Sébastien Küry
A1 Mathilde Nizon
A1 Iqra Ghulam Rasool
A1 Muhammad Yasir Zahoor
A1 Cornelia Kraus
A1 André Reis
A1 Muhammad Iqbal
A1 Kevin Uguen
A1 Severine Audebert-Bellanger
A1 Claude Ferec
A1 Sylvia Redon
A1 Janice Baker
A1 Yunhong Wu
A1 Guiseppe Zampino
A1 Steffan Syrbe
A1 Ines Brosse
A1 Rami Abou Jamra
A1 William B. Dobyns
A1 Lilian L. Cohen
A1 Pankaj B. Agrawal
A1 Alan Beggs
A1 Timothy W. Yu
YR 2020
UL http://medrxiv.org/content/early/2020/09/13/2020.09.09.20187104.abstract
AB Purpose We describe a novel neurobehavioral syndrome of autism spectrum disorder, intellectual disability, and attention deficit/hyperactivity disorder associated with de novo or inherited deleterious variants in members of the RFX family of genes. RFX genes are evolutionarily conserved transcription factors that act as master regulators of central nervous system development and ciliogenesis.Methods We assembled a cohort of 36 individuals (from 31 unrelated families) with de novo mutations in RFX3, RFX4, and RFX7. We describe their common clinical phenotypes and present bioinformatic analyses of expression patterns and downstream targets of these genes as they relate to other neurodevelopmental risk genes.Results These individuals share neurobehavioral features including autism spectrum disorder (ASD), intellectual disability, and attention-deficit/hyperactivity disorder (ADHD); other frequent features include hypersensitivity to sensory stimuli and sleep problems. RFX3, RFX4, and RFX7 are strongly expressed in developing and adult human brain, and X-box binding motifs as well as RFX ChIP-seq peaks are enriched in the cis-regulatory regions of known ASD risk genes.Conclusion These results establish deleterious variation in RFX3, RFX4, and RFX7 as important causes of monogenic intellectual disability, ADHD and ASD, and position these genes as potentially critical transcriptional regulators of neurobiological pathways associated with neurodevelopmental disease pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJL was supported by award T32GM007753 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. BZ was supported by the Manton Center Pilot Project Award and Rare Disease Research Fellowship. JEP and JRL were supported in part by the National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542). KU, SAB, CF, and SR were supported by the French Ministry of Health and the Health Regional Agency from Bretagne, Pays de la Loire and Centre Val de Loire (HUGODIMS 2, 2017). The DDD study is supported by the Wellcome Trust and the UK Department of Health Innovation Challenge Fund [HICF-1009-003] and the Wellcome Trust Sanger Institute [grant no. WT098051] (Nature 2015;519:223-8). TWY was supported by grant nos. NIH/NIMH R01MH113761, NICHD/NHGRI/NIH U19HD077671 and NIH/NICHD U24HD0938487, and by a SFARI Pilot Research Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Boston Children's Hospital IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in this manuscript is either provided in the main text/ supplementary material, or appropriately referenced (where derived from pre-existing, publicly accessible datasets).